menu
    • menu
    [{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"PharmaMar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eczac\u0131ba\u015f\u0131 Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131 Group \/ Eczac\u0131ba\u015f\u0131 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eczac\u0131ba\u015f\u0131 Group \/ Eczac\u0131ba\u015f\u0131 Pharmaceuticals"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"[177Lu]Ludotadipep","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem"}]

    Find Clinical Drug Pipeline Developments & Deals by Eczacıbaşı Group

    Menu

    Eczacıbaşı Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eczacıbaşı-Monrol Nuclear Products

                            Turkey arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eczacıbaşı-Monrol Nuclear Products

                            Turkey arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : [177Lu]Ludotadipep

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : FutureChem

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Monrol and FutureChem Announced a Clinical Supply Partnership

                            Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.

                            Brand Name : 177Lu-FC705

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : [177Lu]Ludotadipep

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : FutureChem

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eczacıbaşı Group

                            Turkey arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eczacıbaşı Group

                            Turkey arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : PharmaMar

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey

                            Details : Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Sma...

                            Brand Name : Zepzelca

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 22, 2021

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : PharmaMar

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth